This afternoon, Churchill Capital Corp. (CCC), released the details of their shareholder vote to approve their merger with Clarivate Analytics, and it’s pretty much what you would expect – a landslide. There were, however, 138,590 votes in the “no” column, but that only represents 0.2% of the total number of shares voted. As a reminder, per Churchill’s proxy, if a shareholder does not vote or forgets to vote, that is counted as an abstention, so presumably, 138,590 specifically voted “no”.
As far as the number of redemptions (if any) or how much was left in trust post-vote, that information was not provided. We’ll have to wait for further filings to check those results.
Nonetheless, this was an overwhelmingly positive vote. Focusing on 138,590 “no” votes out of 68,291,728 total is like worrying about the postage for a really huge tax bill. Just spring for certified mail.
Summary of results below and you can find the results for the other proposals HERE.
Proposal to approve the business combination:
| FOR | AGAINST | ABSTENTIONS |
| 68,153,138 | 138,590 | 0 |
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...